Pricing Log in Create free account
Tuesday 13 October 2026 Export ASMB’s income statement to Excel — free account

Assembly Biosciences, Inc.

ASMB Healthcare Biotechnology

Assembly Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $72.3 million, up 153.5% from fiscal 2024. In the quarter to June 2026, revenue grew 38.9%, EPS grew 85.0% and free cash flow grew 7.58%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

20.69 2.08 −9.13%
Market cap
$463.6M
P/E
22.3×
Fwd P/E
−21.1×
Dividend yield
—
F-score
4/9
Altman Z
1.06
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.01
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — 2 — — 1 — — — —
Insider Ownership 22.62%

Capital & Financial Ratios $m

Market Cap 463.61
Revenue 74.85
Net Income (0.04)
Free Cash Flow (38.57)
Net Debt (320.36)
Current Ratio 13.99 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 22.32
Fwd P/E (21.10) (negative: loss-making)
P/S ratio 5.74
P/B ratio 1.40
Past 5Y EPS Growth —
This Y EPS Growth (10.58%) (below 0%: weak)
Next Y EPS Growth (401.32%) (below 0%: weak)
Next Y revenue growth (12.27%) (below 0%: weak)
Next 5Y EPS Growth 44.88% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.5×, against a ten-year median of 0.5×; over the ten years it ranged from −1.2× in 2024 to 98.3× in 2018.
P/S against its own 10 years 58.39%
10-year low 10-year high
P/B against its own 10 years 38.50%
10-year low 10-year high
EV/Sales against its own 10 years 14.89%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 130 112 248 320
Receivables 0 — 1 1
Inventory — — — —
Other — — — —
134 116 255 328
2023 2024 2025 Q'26
Payables 0 1 1 1
ST’ Debt — — — —
Other — — — —
39 48 49 23

Compound Annual Growth %

10y 5y 3y
Sales — 35.27% 126.12%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 5.70% (2.99%) 35.74%

Revenue $m

Mar Jun Sep Dec Year
’26 8 13 — — —
’25 9 10 11 42 72
’24 6 9 7 7 29
’23 — — — — 7
’21 — — 6 — 6
’20 4 39 35 1 79
’19 4 3 4 5 16
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (22) (15) — — —
’25 (23) (17) (15) 14 (41)
’24 (18) (17) (15) 0 (51)
’23 (23) (14) (14) 74 23
’22 (28) (18) (20) (19) (84)
’21 (33) (22) (19) (19) (93)
’20 (25) (23) 11 (25) (63)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (22) (15) — — —
’25 (23) (17) (15) 14 (41)
’24 (18) (17) (15) 0 (51)
’23 (23) (14) (14) 74 23
’22 (28) (18) (20) (19) (85)
’21 (36) (22) (19) (19) (96)
’20 (25) (24) 11 (25) (63)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.54) (0.20) — — —
’25 (1.17) (1.33) (0.72) 2.48 (0.55)
’24 (1.66) (1.98) (1.51) (1.57) (6.69)
’23 (4.44) (3.84) (3.24) (1.75) (13.38)
’22 (5.76) (6.12) (5.76) (5.52) (23.05)
’21 (8.28) (6.60) (4.92) (16.45) (36.01)
’20 (9.12) 2.28 (1.08) (13.32) (21.01)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 51.96 142.20 222.96 97.56 57.36 24.36 9.84 7.68 9.12 7.75

Analyst estimates 2026–2028

Powerpack
High 174.00 628.44 808.32 308.16 334.08 84.24 29.40 21.36 19.93 39.71
People
People Employees 69 79 95 115 139 102 68 65 73 73
Revenue/emp, $m 0.00 0.11 0.16 0.14 0.57 0.06 0.00 0.11 0.39 0.99
Income, $m
Income, $m Revenue — 9 15 16 79 6 — 7 29 72
Gross margin, % 0.00 100.00 100.00 100.00 100.00 100.00 0.00 100.00 100.00 100.00
EBT (45) (52) (90) (98) (62) (132) (93) (61) (40) (6)
EBT margin, % 0.00 (575.00) (605.59) (616.48) (78.57) (2,116.82) 0.00 (854.32) (139.72) (8.47)
Net income (44) (43) (91) (98) (62) (130) (93) (61) (40) (6)
Depreciation 0 0 0 (1) 1 43 1 (1) (4) (2)
Per share, $
Per share, $ Revenue 0.00 6.10 7.79 7.30 26.81 1.73 0.00 1.57 4.75 6.45
Earnings (30.85) (28.93) (47.78) (44.66) (21.01) (36.01) (23.05) (13.38) (6.69) (0.55)
Cash flow (24.31) 1.26 (34.20) (38.43) (21.33) (25.91) (20.94) 4.97 (8.51) (3.67)
Capex (0.10) (0.58) (0.18) (0.71) (0.16) (0.62) (0.03) (0.05) 0.00 (0.01)
Free cash flow (24.41) 0.67 (34.38) (39.14) (21.49) (26.53) (20.96) 4.92 (8.52) (3.67)
Book value 55.67 76.50 110.91 124.90 81.52 46.86 20.49 8.98 5.56 18.44
Shares, m 1 1 2 2 3 4 4 5 6 11
Valuation, ×
Valuation, × P/E — 0.00 0.00 0.00 0.00 0.00 — 0.00 0.00 0.00
P/S — 91.05 34.83 33.64 2.71 1.24 — 0.56 3.32 5.27
P/B — 7.26 2.45 1.97 0.89 0.60 — 1.11 2.84 1.84
EV/Sales — 77.75 20.10 16.48 (0.03) (0.56) — (1.04) (0.61) 1.84
EV/FCF — 824.76 (4.56) (3.07) 0.03 0.48 — (3.76) 0.34 (3.24)
Cash, $m
Cash, $m Operating cash flow (35) 2 (65) (84) (63) (93) (84) 23 (51) (41)
Capex 0 (1) 0 (2) 0 (2) 0 0 0 0
Free cash flow (35) 1 (65) (86) (63) (96) (85) 23 (51) (41)
Balance, $m
Balance, $m Working capital 46 110 204 258 200 138 81 95 68 206
Total debt — — — 12 10 6 3 — — —
Net debt (53) (120) (218) (274) (216) (147) (92) (130) (112) (248)
Shareholders’ equity 80 113 211 273 241 169 83 41 33 207
Returns, %
Returns, % ROA (38.18) (32.02) (41.50) (32.12) (19.95) (54.75) (63.58) (51.32) (31.39) (3.25)
ROIC (105.14) 0.00 0.00 0.00 (167.54) (371.85) 0.00 0.00 0.00 0.00
ROE (44.57) (44.36) (56.06) (40.36) (24.19) (63.42) (74.00) (98.95) (107.92) (5.10)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Assembly Biosciences, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ARVN Arvinas, Inc. $499.6M 57.3× — (loss-making) +1,014.73% (above 0%: growing) n/m +49.79% (above 0%: growing) 96.40% 65.72% Compare
EPRX Eupraxia Pharmaceuticals Inc. $491.7M — (loss-making) — — n/m −56.41% (below 0%: shrinking) — 0.00% Compare
MPLT MapLight Therapeutics, Inc. $490.7M — (loss-making) — — n/m −31.91% (below 0%: shrinking) — 0.00% Compare
AUTL Autolus Therapeutics PLC Sponsored ADR $481.8M — (loss-making) — (loss-making) +118.37% (above 0%: growing) n/m +67.55% (above 0%: growing) 55.20% (95.95%) Compare
OVID Ovid Therapeutics $480.4M — (loss-making) — (loss-making) +463.85% (above 0%: growing) n/m −268.54% (below 0%: shrinking) 100.00% (2,141.61%) Compare
ASMB Assembly Biosciences, Inc. $479.1M 22.3× — (loss-making) +38.94% (above 0%: growing) n/m +7.58% (above 0%: growing) 100.00% (47.44%)
YDES YD Bio Limited $476.8M — — — — — — — Compare
RZLT Rezolute, Inc. $471.1M — (loss-making) — — n/m +40.23% (above 0%: growing) 0.00% 0.00% Compare
ENTX Entera Bio Ltd. $462.4M — (loss-making) — (loss-making) +200.00% (above 0%: growing) n/m −108.86% (below 0%: shrinking) 0.00% 0.00% Compare
Median of peers $481.1M — — +331.93% — −31.91% 55.20% 0.00%

All 614 Biotechnology stocks →

Assembly Biosciences, Inc. (ASMB) key facts

  • Strength: Assembly Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $72.3 million, up 153.5% from fiscal 2024.
  • Assembly Biosciences, Inc. (ASMB) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 13, 2026, ASMB traded at $20.95, a market capitalization of $463.6 million.
  • Return on equity was −5.10% and debt-to-equity 0.00.
  • Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 1.06 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Assembly Biosciences, Inc. (ASMB) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/ASMB · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com